Immunotherapy (IO) with or without targeted therapy (TT) is the standard treatment for
patients with metastatic clear cell renal cell carcinoma (RCC). The evidence supporting their …

e16507 Background: The Food and Drug Administration (FDA) has approved a variety of
drugs for the treatment of advanced metastatic renal cell carcinoma, including anti-vascular …

e16543 Background: nccRCC accounts for 25% of kidney cancer diagnoses and
encompasses a diverse group of kidney tumors with distinct biology for which trt in the …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …

427 Background: lmmunotherapy is changing the treatment of patients with metastatic renal
cell carcinoma (mRCC). In recent years, many immune checkpoint inhibitors (ICls) have …

Substantial changes have occurred in the systemic treatment paradigm for metastatic renal
cell carcinoma (mRCC) with the development of immune checkpoint inhibitors (ICIs)[1]. To …

Purpose: The Korean Renal Cancer Study Group (KRoCS) provides consensus
recommendations on the role of cytoreductive nephrectomy (CRN) in patients with …

Background The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective To …

Background Recent clinical data has renewed the debate regarding the role of CN for
patients with metastatic RCC (mRCC). Metastatic S/R clear cell RCC is an aggressive …

Objective To describe the dissemination of targeted therapy and its impact on rates of
cytoreductive nephrectomy (CNx) and among privately insured patients with metastatic renal …